Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib
and Sintilimab in advanced colorectal cancer as first-line treatment.